Cargando…
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908811/ https://www.ncbi.nlm.nih.gov/pubmed/35249272 http://dx.doi.org/10.1056/NEJMoa2119451 |
_version_ | 1784665954494447616 |
---|---|
author | Andrews, Nick Stowe, Julia Kirsebom, Freja Toffa, Samuel Rickeard, Tim Gallagher, Eileen Gower, Charlotte Kall, Meaghan Groves, Natalie O’Connell, Anne-Marie Simons, David Blomquist, Paula B. Zaidi, Asad Nash, Sophie Iwani Binti Abdul Aziz, Nurin Thelwall, Simon Dabrera, Gavin Myers, Richard Amirthalingam, Gayatri Gharbia, Saheer Barrett, Jeffrey C. Elson, Richard Ladhani, Shamez N. Ferguson, Neil Zambon, Maria Campbell, Colin N.J. Brown, Kevin Hopkins, Susan Chand, Meera Ramsay, Mary Lopez Bernal, Jamie |
author_facet | Andrews, Nick Stowe, Julia Kirsebom, Freja Toffa, Samuel Rickeard, Tim Gallagher, Eileen Gower, Charlotte Kall, Meaghan Groves, Natalie O’Connell, Anne-Marie Simons, David Blomquist, Paula B. Zaidi, Asad Nash, Sophie Iwani Binti Abdul Aziz, Nurin Thelwall, Simon Dabrera, Gavin Myers, Richard Amirthalingam, Gayatri Gharbia, Saheer Barrett, Jeffrey C. Elson, Richard Ladhani, Shamez N. Ferguson, Neil Zambon, Maria Campbell, Colin N.J. Brown, Kevin Hopkins, Susan Chand, Meera Ramsay, Mary Lopez Bernal, Jamie |
author_sort | Andrews, Nick |
collection | PubMed |
description | BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case–control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. RESULTS: Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks. CONCLUSIONS: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.) |
format | Online Article Text |
id | pubmed-8908811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Massachusetts Medical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-89088112022-03-21 Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant Andrews, Nick Stowe, Julia Kirsebom, Freja Toffa, Samuel Rickeard, Tim Gallagher, Eileen Gower, Charlotte Kall, Meaghan Groves, Natalie O’Connell, Anne-Marie Simons, David Blomquist, Paula B. Zaidi, Asad Nash, Sophie Iwani Binti Abdul Aziz, Nurin Thelwall, Simon Dabrera, Gavin Myers, Richard Amirthalingam, Gayatri Gharbia, Saheer Barrett, Jeffrey C. Elson, Richard Ladhani, Shamez N. Ferguson, Neil Zambon, Maria Campbell, Colin N.J. Brown, Kevin Hopkins, Susan Chand, Meera Ramsay, Mary Lopez Bernal, Jamie N Engl J Med Original Article BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case–control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. RESULTS: Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks. CONCLUSIONS: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.) Massachusetts Medical Society 2022-03-02 /pmc/articles/PMC8908811/ /pubmed/35249272 http://dx.doi.org/10.1056/NEJMoa2119451 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
spellingShingle | Original Article Andrews, Nick Stowe, Julia Kirsebom, Freja Toffa, Samuel Rickeard, Tim Gallagher, Eileen Gower, Charlotte Kall, Meaghan Groves, Natalie O’Connell, Anne-Marie Simons, David Blomquist, Paula B. Zaidi, Asad Nash, Sophie Iwani Binti Abdul Aziz, Nurin Thelwall, Simon Dabrera, Gavin Myers, Richard Amirthalingam, Gayatri Gharbia, Saheer Barrett, Jeffrey C. Elson, Richard Ladhani, Shamez N. Ferguson, Neil Zambon, Maria Campbell, Colin N.J. Brown, Kevin Hopkins, Susan Chand, Meera Ramsay, Mary Lopez Bernal, Jamie Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title_full | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title_fullStr | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title_full_unstemmed | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title_short | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant |
title_sort | covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908811/ https://www.ncbi.nlm.nih.gov/pubmed/35249272 http://dx.doi.org/10.1056/NEJMoa2119451 |
work_keys_str_mv | AT andrewsnick covid19vaccineeffectivenessagainsttheomicronb11529variant AT stowejulia covid19vaccineeffectivenessagainsttheomicronb11529variant AT kirsebomfreja covid19vaccineeffectivenessagainsttheomicronb11529variant AT toffasamuel covid19vaccineeffectivenessagainsttheomicronb11529variant AT rickeardtim covid19vaccineeffectivenessagainsttheomicronb11529variant AT gallaghereileen covid19vaccineeffectivenessagainsttheomicronb11529variant AT gowercharlotte covid19vaccineeffectivenessagainsttheomicronb11529variant AT kallmeaghan covid19vaccineeffectivenessagainsttheomicronb11529variant AT grovesnatalie covid19vaccineeffectivenessagainsttheomicronb11529variant AT oconnellannemarie covid19vaccineeffectivenessagainsttheomicronb11529variant AT simonsdavid covid19vaccineeffectivenessagainsttheomicronb11529variant AT blomquistpaulab covid19vaccineeffectivenessagainsttheomicronb11529variant AT zaidiasad covid19vaccineeffectivenessagainsttheomicronb11529variant AT nashsophie covid19vaccineeffectivenessagainsttheomicronb11529variant AT iwanibintiabdulaziznurin covid19vaccineeffectivenessagainsttheomicronb11529variant AT thelwallsimon covid19vaccineeffectivenessagainsttheomicronb11529variant AT dabreragavin covid19vaccineeffectivenessagainsttheomicronb11529variant AT myersrichard covid19vaccineeffectivenessagainsttheomicronb11529variant AT amirthalingamgayatri covid19vaccineeffectivenessagainsttheomicronb11529variant AT gharbiasaheer covid19vaccineeffectivenessagainsttheomicronb11529variant AT barrettjeffreyc covid19vaccineeffectivenessagainsttheomicronb11529variant AT elsonrichard covid19vaccineeffectivenessagainsttheomicronb11529variant AT ladhanishamezn covid19vaccineeffectivenessagainsttheomicronb11529variant AT fergusonneil covid19vaccineeffectivenessagainsttheomicronb11529variant AT zambonmaria covid19vaccineeffectivenessagainsttheomicronb11529variant AT campbellcolinnj covid19vaccineeffectivenessagainsttheomicronb11529variant AT brownkevin covid19vaccineeffectivenessagainsttheomicronb11529variant AT hopkinssusan covid19vaccineeffectivenessagainsttheomicronb11529variant AT chandmeera covid19vaccineeffectivenessagainsttheomicronb11529variant AT ramsaymary covid19vaccineeffectivenessagainsttheomicronb11529variant AT lopezbernaljamie covid19vaccineeffectivenessagainsttheomicronb11529variant |